Designation: Professor
Department: Department of Biomedical Sciences and Disease
University: New England College of Optometry
Country: United States
Koevary earned a Ph.D in Biomedical Sciences from the City University of New York, New York. He is currently Chairman and Professor of Department of Biomedical Sciences and Disease at New England College of Optometry, USA. He has received several professional awards. Most of his work is patented. He is an active member of many societies. He attended many international conferences. He published articles in many national and international journals.
Focus of his research in recent years has been in the examination of the efficacy of using topically applied drugs to treat diseases of the posterior segment of the eye,developing a methodology for the delivery of monoclonal antibodies and neurotrophic factors to the retina for the treatment of macular degeneration and diabetic retinopathy. Most recently, he shifted gears towards the examination of ways of preventing tumour cell growth using various compounds including rose bengal and amniotic fluid-derived stem cells in ovarian cancer and retinoblastoma models.
Boffin Access Limited is committed to maintaining the integrity of the scholarly record to researchers. Therefore violation of professional ethical codes may lead to retract articles. Article(s) may be retracted if it is found to have serious flaws, reported misconduct research, constitute copyright infringement and plagiarism.
To help avoid the incorrect or misleading publications, please drop your message to
Send Information
Enter your e-mail address to stay informed about published articles, issue releases and latest updates on journal activities.
We openly welcome feedback and constructive criticism. Your compliments, concerns and suggestions regarding our services will prove enormously helpful in making them even better.
Do you have an idea or suggestion that can influence the Open Access community? Send an email to: support@boffinaccess.org
Copyright © 2020 Boffin Access Limited.
